Skip to main content

Table 2 Tumor response rate and survival according to therapy line

From: Phase II study of weekly paclitaxel and capecitabine in patients with metastatic or recurrent esophageal squamous cell carcinoma

Efficacy endpoints

1st line (n = 12)

2nd line (n = 20)

Overall (n = 32)

 

No.

(%)

No.

(%)

No.

(%)

Complete response

2

(16.7)

1

(5.0)

3

(9.4)

Partial response

7

(58.3)

8

(40.0)

15

(46.9)

Stable disease

0

(0.0)

6

(30.0)

6

(18.7)

Progressive disease

3

(25.0)

5

(25.0)

8

(25.0)

Overall response rate

9

(75.0)

9

(45.0)

18

(56.3)*

  1. *(95%Confidence Interval; 39.0-73.4)